Exodus Point Capital Management, LP Aadi Bioscience, Inc. Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$4.84 - $7.13 $828,840 - $1.22 Million	171,248 Added 125.45%	307,759 $1.49 Million
Q2 2023 Aug 10, 2023	BUY	$6.84 - $8.56 $237,183 - $296,826	34,676 Added 34.05%	136,511 $934,000
Q1 2023 May 11, 2023	BUY	$6.85 - $13.0 $181,593 - $344,630	26,510 Added 35.19%	101,835 $737,000
Q4 2022 Feb 13, 2023	BUY	$11.99 - $14.5 $213,362 - $258,027	17,795 Added 30.93%	75,325 $966,000
Q3 2022 Nov 10, 2022	BUY	$12.03 - $14.22 $196,858 - $232,696	16,364 Added 39.75%	57,530 $813,000
Q2 2022 Aug 19, 2022	SELL	$11.57 - $17.92 $31,308 - $48,491	-2,706 Reduced 6.17%	41,166 $507,000
Q1 2022 May 13, 2022	BUY	$16.65 - $24.97 $730,468 - $1.1 Million	43,872 New	43,872 $745,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $63.1M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.